Philip Morris International
PM
$191.06
+0.68%
Philip Morris International Inc. (PM) is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco (IQOS), vapes (Veev), and oral nicotine (Zyn), primarily outside the U.S. As the international arm spun off from Altria in 2008, PMI has established itself as a leader in the industry's transformation toward smoke-free alternatives, with IQOS and Zyn dominating their respective categories in most markets. The current investor narrative centers on PMI's accelerating transition to reduced-risk products, which now account for a significant portion of revenue, while navigating regulatory shifts such as the FDA's recent nicotine pouch decision and managing the secular decline of traditional cigarettes. The stock has gained 13.3% over the past year, reflecting optimism about its smoke-free growth strategy, but recent price volatility suggests debates over regulatory headwinds and valuation sustainability.…
PM
Philip Morris International
$191.06
Related headlines
Investment Opinion: Should I buy PM Today?
Based on the analysis, PM is rated a Buy, with a thesis that its smoke-free product transition is driving sustainable growth at a reasonable valuation. The consensus analyst rating is bullish, with an average target price of $207.13, implying 13.5% upside, which supports a positive outlook.
Sign up to view all
PM 12-Month Price Forecast
The AI assessment is bullish on PM, driven by its strong revenue growth, high margins, and attractive PEG ratio. The company's successful transition to reduced-risk products is a key differentiator, and the low beta provides defensive qualities. However, regulatory risks and a premium absolute valuation temper confidence. The stance would be upgraded if regulatory clarity improves and growth accelerates, or downgraded if Zyn faces severe restrictions or revenue growth decelerates below 7%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $207.27 and implied upside of +8.5% versus the current price.
Average Target
$207.27
0 analysts
Implied Upside
+8.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $230
Analyst target range
PM is covered by 15 analysts, with a consensus recommendation leaning bullish, though the data does not specify the exact Buy/Hold/Sell distribution. The average target price is $207.13, implying a 13.5% upside from the current price of $182.53, while the low target of $175.00 suggests a 4.1% downside and the high target of $230.00 implies a 26.0% upside. The wide range between the low and high targets indicates significant uncertainty among analysts, likely due to regulatory risks and the pace of smoke-free product adoption. Recent ratings actions have been predominantly positive, with firms like Morgan Stanley and Needham reiterating Overweight and Buy ratings, while UBS maintains a Neutral stance, reflecting a balanced but constructive outlook.
Bulls vs Bears: PM Investment Factors
PM presents a balanced but slightly bullish case, with strong revenue growth, high margins, and attractive valuation on a PEG basis offset by regulatory risks and a premium absolute valuation. The bull case is supported by accelerating smoke-free product adoption and analyst upside, while the bear case hinges on regulatory headwinds and the secular decline of combustibles. The most critical tension is whether Zyn and IQOS can sustain double-digit growth despite regulatory pressures, as this will determine if PM can justify its current valuation and achieve the earnings growth implied by its forward PE. Currently, the evidence slightly favors the bulls, given the strong Q1 results and low PEG, but regulatory developments remain the key swing factor.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 9.1% YoY to $10.15B, up from 8.9% in Q1 2025, signaling accelerating demand for reduced-risk products like IQOS and Zyn. This growth is outpacing the broader tobacco industry's stagnation, driven by successful smoke-free product adoption.
- High Gross and Operating Margins: Gross margin stands at 67.1% and operating margin at 36.7%, reflecting premium pricing power and operational efficiency. These robust margins provide a strong foundation for earnings growth and cash generation, supporting continued investment in smoke-free innovation.
- Undervalued on PEG Ratio: With a PEG ratio of 0.36, PM trades at a significant discount to its growth rate, suggesting the market is underpricing its earnings potential. This low PEG indicates that the stock offers attractive value relative to its expected EPS growth of ~10%.
- Analyst Targets Imply Upside: The average analyst target price of $207.13 implies a 13.5% upside from the current price of $182.53, with the high target of $230 suggesting a 26% potential gain. Recent ratings from Morgan Stanley and Needham (Overweight/Buy) reflect confidence in PM's strategic direction.
Bearish
- Regulatory Overhang on Nicotine Pouches: The FDA's recent decision on nicotine pouches introduces uncertainty for Zyn, a key growth driver. Regulatory restrictions could limit marketing, flavor options, or availability, potentially slowing the rapid adoption that has fueled recent revenue growth.
- High Valuation on Absolute Basis: PM trades at a trailing PE of 22.1x and forward PE of 19.9x, which is a premium to the broader market and its own historical average. This leaves limited room for multiple expansion, making the stock vulnerable to earnings disappointments.
- Declining Combustible Volumes: Traditional cigarette volumes continue to decline globally, and PM's combustible segment still generates over half of revenue ($5.77B in Q1 2026). If smoke-free products fail to fully offset these declines, overall revenue growth could stall.
- High Payout Ratio Limits Flexibility: PM's dividend payout ratio is 76%, leaving limited retained earnings for reinvestment or debt reduction. This high payout could constrain the company's ability to invest in new growth initiatives or weather unexpected downturns.
PM Technical Analysis
PM is currently in a recovery phase within a broader uptrend, as the stock trades at $182.53, up 13.3% over the past year, yet it sits 12.1% below its 52-week high of $207.76 and 28.4% above its 52-week low of $142.11. The price is positioned at 62.3% of the 52-week range, indicating a middle-ground stance—neither overextended at highs nor deeply discounted at lows, which often suggests a consolidation phase after a strong rally. The stock's beta of 0.395 implies it is significantly less volatile than the market, making it a defensive holding, but its recent pullback from the July peak of $200.17 to $182.53 highlights that even low-beta names can experience meaningful corrections.
Beta
0.40
0.40x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+13.8%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | -1.1% |
| 3m | +3.7% | +3.0% |
| 6m | +9.4% | +15.4% |
| 1y | +13.8% | +16.2% |
| ytd | +19.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory remains robust, with Q1 2026 revenue of $10.15 billion, up 9.1% year-over-year, accelerating from the 8.9% growth seen in Q1 2025. The combustible products segment contributed $5.77 billion, while reduced-risk products generated $4.38 billion, underscoring the growing importance of smoke-free alternatives as traditional cigarette volumes decline. This growth is driven by strong demand for IQOS and Zyn, which are offsetting volume declines in combustibles, and the company's ability to raise prices in an inflationary environment. The 9.1% YoY growth in Q1 2026 is a positive signal, though it remains to be seen if this pace can be sustained given regulatory pressures on nicotine pouches.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given PM's positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 22.1x, while the forward PE is 19.9x, implying the market expects earnings growth of approximately 10% over the next year. This forward discount suggests optimism about continued EPS expansion, supported by the company's focus on higher-margin reduced-risk products. PM's PEG ratio of 0.36 indicates that the stock is undervalued relative to its growth rate, making it an attractive value proposition for investors seeking both income and growth.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, PM carries a significant debt load, with a debt-to-equity ratio of -4.89 (negative equity due to buybacks) and interest expenses of $237M in Q1 2026. While operating cash flow is strong (FCF TTM of $10.7B), the high payout ratio of 76% limits financial flexibility, and the negative equity position could be a concern if earnings decline. Revenue concentration in combustibles (57% of Q1 revenue) exposes PM to volume declines, though reduced-risk products are growing to offset this. Margin pressure could arise if regulatory costs or competition force price investments, but current gross margins of 67% provide a cushion.